Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

ATM and TGFB1 genes polymorphisms in prediction of late complications of chemoradiotherapy in patients with locally advanced cervical cancer

S. Paulikova, J. Petera, I. Sirak, M. Vosmik, M. Drastikova, L. Dusek, M. Cvanova, R. Soumarova, J. Spacek, M. Beranek

. 2014 ; 61 (1) : 70-76.

Jazyk angličtina Země Slovensko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15001955

Grantová podpora
NT11334 MZ0 CEP - Centrální evidence projektů

The purpose of our study was to evaluate a possible correlation between genetic polymorphisms in ATM and TGFB1 genes and late toxicity of chemoradiotherapy for locally advanced cervical cancer. Fifty five patients with FIGO stage IIB and higher without a disease recurrence with a mean follow up of 6 years were included. Late toxicity was assessed by EORTC/RTOG late toxicity criteria. Univariate and multivariate logistic regression model was used for statistical analysis. Degree of association between polymorphisms and late toxicity of chemotherapy was assessed on the basis of phi-coefficient () as well. We did not find any association between 5557G>A polymorphism in the ATM gene or single TGFB1 polymorphisms and late toxicity. TGFB1 compound homozygosity (-1552delAGG, -509C>T, L10P) was a significant predictive factor of grade III-IV and any grade of complications in both univariate and multivariate logistic regression analyses and statistical significance of association between polymorphisms and late toxicity of chemoradiotherapy was confirmed also by the evaluation of phi-coefficient (). We conclude that haplotypes instead of single nucleotide polymorphic sites in the genes may better characterize the individual radiosensitivity.

000      
00000naa a2200000 a 4500
001      
bmc15001955
003      
CZ-PrNML
005      
20240904092550.0
007      
ta
008      
150120s2014 xo f 000 0|eng||
009      
AR
035    __
$a (PubMed)24195511
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xo
100    1_
$a Paulíková, Simona $7 xx0245927 $u Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Czech Republic
245    10
$a ATM and TGFB1 genes polymorphisms in prediction of late complications of chemoradiotherapy in patients with locally advanced cervical cancer / $c S. Paulikova, J. Petera, I. Sirak, M. Vosmik, M. Drastikova, L. Dusek, M. Cvanova, R. Soumarova, J. Spacek, M. Beranek
520    9_
$a The purpose of our study was to evaluate a possible correlation between genetic polymorphisms in ATM and TGFB1 genes and late toxicity of chemoradiotherapy for locally advanced cervical cancer. Fifty five patients with FIGO stage IIB and higher without a disease recurrence with a mean follow up of 6 years were included. Late toxicity was assessed by EORTC/RTOG late toxicity criteria. Univariate and multivariate logistic regression model was used for statistical analysis. Degree of association between polymorphisms and late toxicity of chemotherapy was assessed on the basis of phi-coefficient () as well. We did not find any association between 5557G>A polymorphism in the ATM gene or single TGFB1 polymorphisms and late toxicity. TGFB1 compound homozygosity (-1552delAGG, -509C>T, L10P) was a significant predictive factor of grade III-IV and any grade of complications in both univariate and multivariate logistic regression analyses and statistical significance of association between polymorphisms and late toxicity of chemoradiotherapy was confirmed also by the evaluation of phi-coefficient (). We conclude that haplotypes instead of single nucleotide polymorphic sites in the genes may better characterize the individual radiosensitivity.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    02
$a senioři $7 D000368
650    12
$a ATM protein $x genetika $7 D064007
650    12
$a chemoradioterapie $x škodlivé účinky $7 D059248
650    02
$a ženské pohlaví $7 D005260
650    02
$a haplotypy $7 D006239
650    02
$a lidé $7 D006801
650    02
$a logistické modely $7 D016015
650    02
$a lidé středního věku $7 D008875
650    12
$a polymorfismus genetický $7 D011110
650    12
$a transformující růstový faktor beta1 $x genetika $7 D053773
650    12
$a nádory děložního čípku $x genetika $x terapie $7 D002583
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Petera, Jiří, $d 1959- $7 xx0000229 $u Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Czech Republic
700    1_
$a Sirák, Igor $7 xx0135409 $u Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Czech Republic
700    1_
$a Vošmik, Milan, $d 1972- $7 xx0135408 $u Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Czech Republic
700    1_
$a Drastíková, Monika $7 xx0321911 $u Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Czech Republic
700    1_
$a Dušek, Ladislav, $d 1967- $7 mzk2003181727 $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Cvanová, Michaela $7 mub20191032771 $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Soumarová, Renata $7 xx0031806 $u Cancer Centre Novy Jicin, Czech Republic
700    1_
$a Špaček, Jiří, $d 1957- $7 xx0143233 $u Department of Obstetrics and Gynecology, University Hospital Hradec Králové, Czech Republic
700    1_
$a Beránek, Martin, $d 1968- $7 xx0044204 $u Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Czech Republic
773    0_
$t Neoplasma $x 0028-2685 $g Roč. 61, č. 1 (2014), s. 70-76 $w MED00003470
910    __
$a ABA008 $c 659 $b A 1194 $y 4 $z 0
990    __
$a 20150120172009 $b ABA008
991    __
$a 20240904092545 $b ABA008
999    __
$a ok $b bmc $g 1059003 $s 884683
BAS    __
$a 3
BMC    __
$a 2014 $b 61 $c 1 $d 70-76 $i 0028-2685 $m Neoplasma $x MED00003470
GRA    __
$a NT11334 $p MZ0
LZP    __
$a 2015-01/abbo
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace